SERAQUEST RUBELLA IGG— 510(k) K961053

Substantially Equivalent

Quest Intl., Inc.

FDA 510(k) clearance K961053 for SERAQUEST RUBELLA IGG, Substantially Equivalent on 1996-09-04. Applicant: Quest Intl., Inc.. Device class: 2.

Clearance details

Applicant: Quest Intl., Inc.
Product code: Code LFX
Device class: Class 2
Regulation: 21 CFR 866.3510
Advisory panel: Microbiology
Date received: 1996-03-18
Decision date: 1996-09-04
Decision: Substantially Equivalent
Clearance type: Traditional
Location: North Miami, FL, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code LFX

K250588 — Access Rubella IgG2025-11-17
K243168 — Alinity i Rubella IgG2025-06-20
K122397 — LIAISON RUBELLA IGM, LIAISON CONTROL RUBELLA IGM2012-09-06
K093101 — MAGO 4S2011-01-21
K092587 — BIOPLEX 2200 RUBELLA & CMV IGM KIT ON THE BIOPLEX 2200 MULTI ANALYTE DETECTION SYSTEM2010-12-03

More clearances from Quest Intl., Inc.

K091260 — SERAQUEST EBV EA-D IGG TEST2009-06-08
K033915 — MODIFICATION TO SERAQUEST EB VCA IGG2004-01-16
K033780 — MODIFICATION TO SERAQUEST VCA IGM2004-01-15
K023593 — SERAQUEST ANTI-THYROID PEROXIDASE (TPO)2003-02-06
K023592 — SERAQUEST ANTI-THYROGLOBULIN2003-01-06

Data sourced from openFDA. This site is unofficial and independent of the FDA.